Boots has launched a private medical cannabis service in the UK, becoming the first high street pharmacy in Britain to offer specialist medical cannabis prescriptions. Called SureLeaf, the service allows eligible patients aged 25 and above to access specialist assessments for conditions including chronic pain, generalised anxiety disorder and insomnia.
The launch of medical cannabis in Boots UK also includes a research collaboration with the University of Nottingham to examine patient outcomes and prescribing practices, particularly in chronic pain management.
Access to medical cannabis remains restricted to specific circumstances. The Boots’ new SureLeaf service initiative introduces another private medical cannabis treatment option for patients who have not received adequate relief from conventional treatments.
What Is The Boots’ New SureLeaf Service?
Boots’ new SureLeaf service operates through Boots Online Doctor and provides specialist-led medical cannabis treatment. Unlike conventional pharmacy services, SureLeaf requires patients to undergo clinical assessments before receiving a prescription.
The service for medical cannabis in Boots UK focuses on people whose symptoms have not improved sufficiently with existing treatments. Boots says its approach combines personalised treatment plans, specialist consultations and regular clinical reviews.
Jamie Kerruish, Chief Healthcare Officer at Boots, said, “Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care.”
The company aims to expand access to specialist healthcare while maintaining clinical oversight throughout treatment.
Who Is Eligible for Boots Medical Cannabis Prescriptions?
The medical cannabis in Boots UK is available to patients aged 25 or older who meet specific medical and clinical requirements. Applicants must have tried conventional treatments without achieving adequate symptom relief.
Boots’ new SureLeaf service covers three main categories:
- Chronic pain: Conditions include fibromyalgia, neuropathic pain, chronic back and neck pain, arthritis, sciatica, chronic migraine and endometriosis-related pelvic pain.
- Generalised anxiety disorder: Patients with a diagnosed anxiety disorder may be considered following specialist assessment.
- Insomnia disorder: People experiencing persistent difficulties falling asleep or staying asleep may also qualify.
However, meeting the UK medical cannabis eligibility criteria does not automatically result in a prescription. Specialists must determine whether treatment is appropriate for each patient’s medical history and circumstances.
How Does Boots Medical Cannabis Treatment Work?
British patients interested in medical cannabis treatment must complete several assessment stages before receiving treatment.
The Boots’ new SureLeaf service follows this process:
- Online eligibility check: Patients complete an initial assessment to determine whether they may qualify.
- Medical history review: Applicants provide information about their health conditions and previous treatments.
- Specialist consultation: Eligible applicants attend a video consultation with a consultant listed on the General Medical Council (GMC) Specialist Register.
- Independent clinical review: A multidisciplinary team, including a second independent consultant, reviews the proposed prescription.
- Treatment and monitoring: Approved patients receive their medication and ongoing clinical support.
Boots plans an initial review of the medical cannabis treatment after 28 days, followed by further assessments at least every three months.
How Much Do Medical Cannabis Products and Treatment Cost?
The medical cannabis in Boots UK offers two treatment formats:
- Cannabis flower: Contains THC (tetrahydrocannabinol), CBD (cannabidiol), or both. Patients use a medically approved vaporiser to administer the prescribed amount.
- Sublingual cannabis oil: Contains CBD, THC or both and is taken under the tongue using a dosing syringe.
Boots advertises cannabis flower from £38 and sublingual oil from £35. Its introductory one-month treatment plan costs £89 and includes an initial specialist assessment, a 10ml starter oil dose and an end-of-month review.
Who Will Examine The Patient Outcomes?
Alongside the launch, Boots has partnered with the University of Nottingham to strengthen research into medical cannabis treatment, particularly for chronic pain.
The University of Nottingham cannabis research programme will examine patient outcomes, prescribing practices and real-world treatment experiences. Researchers will also draw on expertise in pain management, medicines optimisation and healthcare evaluation.
The programme will use validated questionnaires to assess several patient outcomes, including:
- Pain levels and quality of life.
- Sleep patterns and anxiety.
- Mood and treatment progress.
The findings of the medical cannabis in Boots UK could help healthcare professionals better understand which patients may benefit from medical cannabis and how specialists can deliver treatment responsibly.
What Does Medical Cannabis in Boots UK Mean for Patients?
Medical cannabis became legal for specialist prescribing in the UK in November 2018. However, NHS access remains restricted to specific circumstances, including certain forms of severe epilepsy, chemotherapy-related nausea and vomiting, and muscle stiffness associated with multiple sclerosis.
Most medical cannabis prescriptions in UK currently come through private specialist clinics.
With medical cannabis in Boots UK, the company introduces another private treatment pathway through an established high street pharmacy brand. However, questions around clinical effectiveness and patient safety remain important.










